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Abstract 17 
Scientific progress on the human gut microbiome comes at an incredible pace and breadth. 18 
Many prevalent gut species can now be represented by sequenced genomes and have been 19 
linked to a wide range of factors in association studies, revealing that known co-variates of 20 
microbiome composition only account for a small fraction of observed variation. Methodological 21 
advances such as absolute quantification, increased taxonomic resolution to levels subordinate 22 
to species, or refined, stratified study populations might improve this situation, but need to be 23 
complemented by efforts towards better functional understanding of the microbiome as an 24 
ecological system. Baseline longitudinal cohorts and perturbation experiments are essential in 25 
this regard, combining insights from in vitro, in vivo and in natura approaches. Yet, the biggest 26 
challenge ahead lies in transforming this knowledge into actionable items for targeted gut 27 
microbiome modulation. 28 
29 
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The human microbiota is the focus of one of the most dynamic research fields of our time, and 30 
most efforts are directed at the gastrointestinal tract which harbors most of our microbes. In the 31 
past decade, our understanding of the organisms inhabiting our gut, their functionality and their 32 
roles in human health and disease has advanced greatly, facilitated by fast technological 33 
development. Research on the gut microbiome is progressing through several steps that mirror 34 
those of other fields on other biological systems: (i) compilation of parts lists, (ii) association of 35 
the system or its components to external factors, (iii) establishment of functional knowledge, and 36 
(iv) translation of that knowledge into applications. For the gut microbiome, this is reflected in 37 
the following developments. 38 
(i) The compilation of gut microbiome ‘parts lists’ has been in full swing for more than a decade 39 
and is now almost complete, for the dominating prokaryotic domains, and at the resolution of 40 
genera and species. Several studies established the baseline structure and function of the 41 
microbiome – that is, lists of species and their genes – with major contributions from two large 42 
collaborative efforts of the MetaHIT (MetaHIT Consortium et al., 2014; Qin et al., 2010) and 43 
Human Microbiome Project (HMP, The Human Microbiome Jumpstart Reference Strains 44 
Consortium et al., 2010; The Human Microbiome Project Consortium, 2012) consortia. Although 45 
novel diversity continues to be discovered, in particular at subspecies and strain level, and 46 
although a large fraction of microbial genes remains functionally uncharacterized, the census of 47 
the most dominant lineages in industrialized populations is arguably approaching completion 48 
(e.g., Zhou et al., 2018). 49 
(ii) Using these parts list, a wealth of studies has probed for associations of the gut microbiome 50 
to disease, host factors or the wider environment. As coverage and scope increase, these have 51 
been collectively referred to as Metagenome-Wide Association Studies (MWAS) (Wang and Jia, 52 
2016), in analogy to Genome-Wide Association Studies (GWAS). Recently, MWAS have 53 
reached population level, as large-scale cross-sectional studies (Falony et al., 2016; 54 
Zhernakova et al., 2016) started to provide an integrated view of the relative impact of various 55 
host and environmental factors on microbiome composition (see Box 1). 56 
(iii) Associations identified by MWAS are observational, can be indirect or confounded by 57 
underlying factors, and do not easily translate into causal links. However, for a functional 58 
understanding of a complex system such as the gut microbiome, it is necessary to connect parts 59 
lists (1D) to networks (2D) in a spatial (3D) and temporal (4D) context (Raes and Bork, 2008), 60 
and this requires adapted concepts (see below) and methodological approaches (see Box 2). 61 
Although the study of the microbiome’s taxa interaction networks (2D), i.e. the interactions 62 
between its parts (1D), is ongoing, the inference of species interactions from cross-sectional 63 
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data remains challenging (Weiss et al., 2016). This is in part because current readouts (fecal 64 
samples) are still mostly non-quantitative (Vandeputte et al., 2017c) and poorly reflect the 65 
spatial organization of the intestinal tract (3D). Moreover, interactions and microbiome function 66 
are dynamic, and in consequence, individual gut microbes and entire communities need to be 67 
studied in the context of time (4D), though longitudinal studies so far remain scarce. 68 
Perturbation experiments, in particular, enable the study of a system’s dynamics, both at the 69 
level of individual parts and the entire system. An increasing number of intervention studies 70 
adds to our functional understanding of the gut microbiome, but it remains unclear whether 71 
observed responses are generic, stratified or indeed personal (see Box 3). 72 
(iv) Finally, knowledge on the microbiome begins to be translated into applications, and this 73 
entails a move from perturbation to modulation. Perturbations may trigger microbiome shifts, but 74 
most of these are unforeseeable or not intended. Targeted microbiome modulation, preferably 75 
with predictable outcome in terms of response and without side effects, will require a functional 76 
understanding of the system, but also an accepted operational definition of desired “healthy” 77 
endpoints, both intrinsically and in relation to the host. Given these, we expect microbiome 78 
modulation to become a major translational asset in the near future, establishing the 79 
microbiome as a versatile therapeutic target. 80 
In this review, we focus on active and emerging areas in the context of the above (see Figure 81 
1), and especially on studies of the human gut microbiome in natura, with less emphasis on in 82 
vivo work in animal models. Specifically, we highlight recent findings on co-variates associated 83 
to microbiome composition, discuss the strengths and limitations of MWAS, and argue that a 84 
strong push towards longitudinal and perturbation-based study designs is essential for a deeper 85 
functional understanding of the gut microbiome, as well as for the development of microbiome 86 
modulation strategies towards improved health and well-being. 87 
  88 
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Co-variates associated to human gut microbiome composition 89 
Taxonomic composition of the gut microbiome varies greatly between individuals, due to both 90 
microbiome-intrinsic and microbiome-extrinsic factors (see Figure 2). The former depend on the 91 
microbiome’s state, e.g. following maturation during lifetime, which feeds back on itself, e.g. via 92 
taxa interactions. The latter microbiome-extrinsic factors refer to the various environmental 93 
layers that impact on or interact with the gut microbiome. These can explain part of the 94 
observed variation within a population, and can be classified empirically into three overlapping 95 
categories: host-extrinsic factors (i.e., factors influenced by host lifestyle to some extent, such 96 
as dietary habits), host-intrinsic factors (e.g., host genetics), and environmental factors (e.g., the 97 
vertical transmission of maternal strains to neonates, or neocolonization constraints by regional 98 
strain pools; Figure 2). 99 
Many small- to medium-scale MWAS have linked gut microbiome composition to such factors 100 
(see e.g. Lynch and Pedersen, 2016; & Wang and Jia, 2016 for reviews). The majority of these 101 
studies have probed associations of taxonomic composition, usually of genera or species, 102 
whereas functional composition, i.e. gene and functional repertoire, has received less attention, 103 
mostly due to technical and economical constraints. Moreover, only recently have increasing 104 
cohort sizes and comprehensive phenotyping enabled the identification of associations to a 105 
wide range of co-variates with sufficient statistical power (Falony et al., 2016; Goodrich et al., 106 
2016; Turpin et al., 2016; Wang et al., 2016a; Zhernakova et al., 2016). For the first time, such 107 
studies have allowed to quantify the relative contributions of relevant co-variates to microbiome 108 
composition. A key finding has been that even the strongest co-varying factors explain only a 109 
surprisingly small fraction of inter-individual gut microbiome variation, at an estimated combined 110 
effect size in the range of 10-15% (see Box 1). This is, nevertheless, considerably larger than 111 
technical variation (Costea et al., 2017b) and known co-variates should therefore be taken into 112 
account as potential confounders of MWAS (see below). Here, we summarize previous findings 113 
on co-variates of human gut microbiome composition, with a focus on recent work. 114 
 115 
Microbiome state, including disease association and host age 116 
Microbiome compositional state is associated to microbiome-extrinsic factors and shaped by 117 
stochastic or ecological effects (e.g., founder effects when re-seeding from the environment), 118 
but also potentially self-reinforcing. Differences in microbiome state may underlie differential 119 
associations to extrinsic factors, and it is necessary to stratify analyses accordingly (see Box 3). 120 
One such intrinsic stratifying factor is probably the gut enterotype, although it is not clear 121 
whether such community types follow external co-variates such as diet, transit time or 122 
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inflammation, or represent intrinsically different compositional optima with similar functionality, 123 
or both (Costea et al., 2018). Importantly, microbiome associations are often complex and 124 
seldom unidirectional: an external influence may trigger a compositional shift which then 125 
becomes entrenched in an adapted microbiome state, but microbiome state also feeds back to 126 
the host in various ways (e.g., via the production of certain metabolites). 127 
An example of this are the complex associations between microbiome state and diseases from 128 
various medical indication areas (Gilbert et al., 2016; Lynch and Pedersen, 2016; Wang and Jia, 129 
2016). In some, e.g. in the case of colorectal cancer (Zeller et al., 2014) or arthritis (Scher et al., 130 
2013; Tito et al., 2016; Zhang et al., 2015b), individual marker taxa are associated to the 131 
disease, whereas effects on overall composition are mild. Other disease states, in contrast, are 132 
associated to marked shifts in overall compositional features, such as reduced diversity or 133 
richness, as is e.g. the case for obesity (Le Chatelier et al., 2013; Turnbaugh et al., 2009) or 134 
inflammatory bowel disease (IBD, Manichanh et al., 2006; Ott et al., 2004). However, for any 135 
detected association, it is not clear a priori whether microbiome shifts cause the disease or vice 136 
versa, or whether both the disease state and observed microbiome effects are caused by a third 137 
factor. Indeed, a recent meta-study of 28 MWAS datasets found an overlap of microbiome 138 
signatures between different diseases, implying that several reported disease-microbiome links 139 
might be non-specific (Duvallet et al., 2017) and possibly linked to other factors such as transit 140 
time or inflammation (see also Falony et al., 2016). Hence, disease specificity of reported 141 
microbiome markers needs to be established, and preferably tested post hoc, e.g. if 142 
comorbidities or shared symptoms are known, as is the case for colorectal cancer and IBD 143 
(Zeller et al., 2014). 144 
Other well-established differences in microbiome state follow host age (reviewed recently by 145 
(Kundu et al., 2017; Lynch and Pedersen, 2016)). Some age-related transitions are gradual, 146 
while others are more clearly defined, e.g. between neonates and older infants, and can 147 
correlate with lifestyle changes, such as the cessation of breastfeeding. After birth, infants are 148 
colonized by species present in the environment and the mother (Tamburini et al., 2016). Strain-149 
level analyses have recently confirmed that a significant fraction of the developing microbiome 150 
is indeed of maternal origin, but that seeding is selective, as strains from certain phyla are 151 
acquired from the environment (Korpela et al., in press). Neonate and early life microbiome 152 
composition has been linked to several childhood diseases, including atopy and asthma (e.g. by 153 
Fujimura et al., 2016 & Stokholm et al., 2018). It has been suggested that this may be due to 154 
early life disturbances of the microbiome, e.g. as a side effect of antibiotics treatment (reviewed 155 
by Langdon et al., 2016). Other early life events such as birth mode (Caesarean section vs 156 
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vaginal birth) or feeding (breastfeeding vs formula) have been associated to developing or adult 157 
microbiome composition (recently reviewed by Tamburini et al., 2016), but more recent 158 
evidence with regard to longer-term effects is mixed (Chu et al., 2017; Falony et al., 2016). 159 
Diversity increases after infancy and compositional shifts continue more gradually during late 160 
childhood, adolescence and adulthood (Kundu et al., 2017; Odamaki et al., 2016). Elderly 161 
people show signatures of diversity loss, decreased temporal compositional stability and 162 
compositional shifts, all of which are associated to general health, but also to confounders like 163 
diet and housing environment, a more constrained lifestyle (O’Toole and Jeffery, 2015) or 164 
medication (Ticinesi et al., 2017). 165 
 166 
Extrinsic host factors including medication, diet, lifestyle, BMI & stool consistency 167 
A wealth of studies tested associations of the adult gut microbiome to factors that are host-168 
extrinsic (i.e., influenced by host lifestyle at least to some extent). For instance, medication is 169 
emerging as a major co-variate. It is commonly accepted that broad-spectrum antibiotics – 170 
administered to diminish pathogens – impact the gut microbiota as a side effect, both on 171 
immediate and longer timescales (Becattini et al., 2016; Langdon et al., 2016). Perhaps more 172 
surprisingly, an increasing number of reports also link non-antibiotic drugs to microbiome 173 
modulation (reviewed by Le Bastard et al., 2017 and Maier and Typas, 2017). For example, the 174 
type 2 diabetes drug metformin has been shown to have a stronger impact on microbiome 175 
composition than the disease condition itself (Forslund et al., 2015), an effect that has recently 176 
been corroborated in a randomized crossover study (Wu et al., 2017). Similarly, proton pump 177 
inhibitors (Freedberg et al., 2015; Imhann et al., 2016; Jackson et al., 2016), atypical 178 
antipsychotics (Bahr et al., 2015; Flowers et al., 2017; Mäkivuokko et al., 2010) and non-179 
steroidal anti-inflammatory drugs (Rogers and Aronoff, 2016), among others, have been 180 
reported to impact the gut microbiome. In the Flemish Gut Flora Project (FGFP) study, 181 
medication (including antibiotics, but also e.g. anti-histamines and hormones) was found to be 182 
the most important co-variate of microbiome composition (Falony et al., 2016). In a recent large-183 
scale in vitro screen testing 1200 marketed drugs, around half of non-bacterial anti-infectives 184 
and a quarter of all human-targeted drugs were found to inhibit at least one gut commensal 185 
(Maier et al., in press), implying that the effect of medication on the gut microbiome remains 186 
massively underexplored. 187 
Most drugs are defined chemical compounds, but the gut microbiome is regularly confronted 188 
with a complex mix of millions of compounds of dietary origin. As gut commensals contribute to 189 
food digestion, links between diet and the microbiome have been studied for years, at different 190 
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levels of resolution (reviewed e.g. by Flint et al., 2012; Sonnenburg and Bäckhed, 2016). These 191 
include microbiome signatures of broad nutritional categories, such as plant- and animal-based 192 
diets (David et al., 2014; Muegge et al., 2011), and longer-term dietary patterns (Smits et al., 193 
2017; Wu et al., 2011). However, although diet-microbiome associations were confirmed in 194 
cross-sectional studies (Falony et al., 2016; Zeevi et al., 2015; Zhernakova et al., 2016), diet 195 
explained only a low single digit percentage of observed microbiome variation after adjusting for 196 
covariates. This range likely represents a lower limit, as most cross-sectional studies rely on 197 
self-reported dietary data which has various issues (Ioannidis, 2013). 198 
Several lifestyle factors such as cigarette smoking (Biedermann et al., 2013), alcohol usage 199 
(Dubinkina et al., 2017) or physical exercise (Barton et al., 2017; Clarke et al., 2014; Petersen et 200 
al., 2017) have been linked to microbiome composition, but were not among the top-ranking 201 
covariates in recent population studies. Microbiome associations to Body Mass Index (BMI) and 202 
obesity have received considerable attention, with links reported to decreased taxonomic 203 
(Turnbaugh et al., 2009) and functional diversity (Le Chatelier et al., 2013). More recently, this 204 
observation was extended to subspecies resolution (Costea et al., 2017a). A significant but mild 205 
BMI-microbiome link was found in the FGFP (Falony et al., 2016), in line with recent meta-206 
analyses  (Finucane et al., 2014; Sze and Schloss, 2016; Walters et al., 2014). 207 
Stool consistency, as assessed by the Bristol Stool Scale, was the factor with the overall largest 208 
effect size in the FGFP study, accounting for ~5% of observed compositional variation (Falony 209 
et al., 2016). First quantified in a small-scale cohort (Vandeputte et al., 2015), this factor was 210 
recently confirmed in independent cohorts (Tigchelaar et al., 2016; Vandeputte et al., 2017c; 211 
Zhernakova et al., 2016), shown to be independent of water activity (Vandeputte et al., 2017a) 212 
but driven by transit time (Roager et al., 2016). 213 
Clearly, many of these host-extrinsic factors are not independent of each other (e.g., diet and 214 
transit time, BMI and drug usage) and may moreover be linked to host-intrinsic or environmental 215 
factors. It is therefore important to note that many observed microbiome signatures may be 216 
driven by mixed effects. 217 
 218 
Intrinsic host factors such as genetics 219 
Some of the above factors (e.g. BMI) can be partially attributed to genetics. For other factors, a 220 
host genetic component is more tangible: for example, the microbiome is intricately and 221 
reciprocally linked to both the innate and adaptive immune system (reviewed by Belkaid and 222 
Hand, 2014; Hooper et al., 2012; Thaiss et al., 2016), though it has remained challenging to 223 
quantify the immune system’s impact in shaping the gut microbiome independently of other 224 
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factors. Similarly, there is increasing evidence for a reciprocal brain-gut-microbiota axis 225 
(reviewed e.g. by, Carabotti et al., 2015). 226 
Several studies have probed for more direct associations of the microbiome with individual host 227 
genetic loci (reviewed by Hall et al., 2017; Kurilshikov et al., 2017). In a large cross-sectional 228 
study of British twins, relative abundances of several genera were found to be heritable 229 
(Goodrich et al., 2016; 2014); this observation was later corroborated at species level and 230 
extended to function (gene content) on a smaller sub-cohort (Xie et al., 2016). A study of 1,561 231 
North Americans likewise reported taxa heritability, as well as an association of 6 human SNPs 232 
to taxa abundance (Turpin et al., 2016), which has the same order of magnitude as the 9 and 33 233 
loci associated with microbial taxa and pathways, respectively, reported in the Dutch LL-DEEP 234 
cohort (Bonder et al., 2016). A study on a large Northern German cohort reported that 42 235 
human SNPs accounted for ~10% of observed microbiome compositional variation (Wang et al., 236 
2016a). In contrast, a recent re-analysis of the above datasets, extended by 696 Israeli 237 
individuals, estimated that host genetics account for less than 2% of microbiome variation 238 
(Rothschild et al., in press). Overall, the impact of host genetics on the gut microbiota appears 239 
significant, but with very low effect size. Potential discrepancies, such as with subject sex 240 
(reported among the highest-ranking co-variates in the FGFP and LL-DEEP studies) may be 241 
due to indirect effects, e.g. to culturally-influenced behavioral, dietary or proteotypic differences 242 
that cannot be pinpointed to the genome, such as hormone levels. 243 
 244 
Environmental factors 245 
Environmental factors beyond the control of the human host have so far remained understudied, 246 
although geographical patterns in community composition have been reported, possibly 247 
connected to lifestyle (e.g., Suzuki and Worobey, 2014; Yatsunenko et al., 2012). When 248 
extending the taxonomic resolution to subspecies level or to a loose operational definition of 249 
strains, much more defined geographical patterns become obvious (Costea et al., 2017a; 250 
Truong et al., 2017), implying the existence of regional strain pools that harbor different 251 
functionality. Indeed, this can be further refined to the level of household and family where 252 
replacement of gut strains can happen in adulthood (Korpela et al., in press), which may be part 253 
of the reason why family members show a more similar taxonomic composition than non-family 254 
members (Song et al., 2013). The study of effects of household in a broader context, the (built) 255 
environment (Hoisington et al., 2015; Lax et al., 2014), and close contact with nature (Obregon-256 
Tito et al., 2015) will likely reveal further environmental factors influencing the individual gut 257 
microbiome.  258 
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Limitations to studying microbiome associations 259 
Increased cohort sizes, improved study designs and comprehensive metadata surveys have 260 
greatly enhanced the statistical power of MWAS. However, they cannot overcome inherent 261 
limitations to association studies, which are amplified by the complexity and variation of the 262 
underlying data, and which need to be accounted for when interpreting and comparing MWAS 263 
results. 264 
 265 
Technical variation 266 
Like other omics-driven research fields, MWAS are prone to within-study and between-study 267 
batch effects. Two recent meta-analyses of microbiome-disease association studies found that 268 
between-study variation required explicit or implicit batch effect correction (Duvallet et al., 2017; 269 
Pasolli et al., 2016). Almost every step in a typical microbiomics study, including sample 270 
collection and storage (Hang et al., 2014; Song et al., 2016; Vandeputte et al., 2017d; Voigt et 271 
al., 2015), DNA extraction and processing (Costea et al., 2017b; Sinha et al., 2017), and 272 
bioinformatic analyses (Mallick et al., 2017), has been identified as an important source of 273 
technical variation. Indeed, two recent large-scale studies on technical limits to reproducibility 274 
have reported large variation between different workflows as well as between replications of the 275 
same workflow in the same and in different laboratories (Costea et al., 2017b; Sinha et al., 276 
2017). This calls for refined standards, at least in comparison to reference standard operating 277 
procedures (Costea et al., 2017b). 278 
 279 
Specificity and indirect associations 280 
Even if technical variation can be reduced, there are several limitations common to association 281 
studies in general. First, the specificity of any link cannot be proven within such a study. For 282 
instance, discovery of a disease association does not necessarily imply that observed 283 
differences can serve as specific markers without independent replication and comparison with 284 
other phenotypes. Second, any association can be indirect. A case in point are the repeatedly 285 
reported microbiome associations to HIV that have recently been called into question, as most 286 
of the observed signal comes from one of the risk groups, men having sex with men (Noguera-287 
Julian et al., 2016). Even this more direct association is probably confounded by further 288 
untested factors, such as sexual practices, social status or life style. Similarly, confounders are 289 
likely due to question several previously reported disease associations. For example, usage of 290 
the drug metformin caused the majority of the signal underlying earlier reports on a strong 291 
microbiome association with type 2 diabetes (Forslund et al., 2015). A comprehensive survey 292 
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indicated that indeed, a wide range of previously reported associations are at least in part 293 
confounded by secondary factors (Falony et al., 2016). 294 
 295 
Taxonomic resolution and lack of functional characterization 296 
The majority of MWAS to date have relied on amplicon sequencing of the 16S rRNA gene. This 297 
approach is comparatively cost effective and has enabled a dramatic scale-up in cohort sizes. 298 
However, reliable taxonomic classification of current 16S amplicon sequences is generally 299 
limited to genus level (Rodrigues et al., 2017), and several recent analyses indicate that many 300 
taxonomic associations might only emerge at levels subordinate to species (e.g., Costea et al., 301 
2017a; Lloyd-Price et al., 2017). Moreover, amplicon approaches often limit the taxonomic 302 
scope to bacteria and archaea, thereby missing potentially informative signals on eukaryal and 303 
viral members of the gut flora. However, these limits to taxonomic resolution and scope may 304 
soon be overcome as whole-genome shotgun metagenomic sequencing becomes more 305 
affordable (see Box 2). This approach also provides readouts on the microbiome’s gene and 306 
functional repertoires, but this valuable information often remains untapped, partially due to a 307 
blatant lack in functional annotation: a large fraction of gut microbial genes, both from cultured 308 
isolates and metagenomes, is uncharacterized to date. 309 
 310 
Correlation does not imply causation 311 
It has become a scientific truism in microbiome research that correlation does not imply 312 
causation: while causal directionality is trivial for some associations (e.g., antibiotics treatment 313 
impacts the microbiome, and not vice versa), it is difficult or impossible to infer for others, based 314 
on observational data only. Several mathematical approaches for causality inference that have 315 
been applied successfully in other fields start to be adopted for microbiome data, such as 316 
structural equation modeling or Bayesian network inference. However, their wider utilization has 317 
been hampered by constraints on data size and complexity, and many inference frameworks 318 
require repeated (longitudinal) observations (see below). 319 
The gold standard for assessing causality of individual associations are classical, reductionist 320 
approaches, often relying on mouse models. For example, a potentially protective role for 321 
Clostridium immunis was recently discovered in a murine colitis model, using a framework 322 
dubbed microbe-phenotype triangulation (Surana and Kasper, 2017) which satisfies a 323 
“commensal” version of Koch’s postulates (Neville et al., 2018). However, such workflows 324 
require the successful isolation and cultivation of targeted taxa which often remains challenging 325 
in practice. In some cases, MWAS findings are validated experimentally by transplanting human 326 
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fecal microbiota into mouse models (reviewed by Wang and Jia, 2016). However, while murine 327 
models allow for controlled experimental setups, they suffer from several limitations, including 328 
anatomical and physiological differences between the human and murine digestive tract, cage 329 
effects due to coprophagy, fundamentally different microbiome composition with little species 330 
overlap, and different host immune pressures affecting transplanted microbiotas (Hugenholtz 331 
and de Vos, 2017; Nguyen et al., 2015). In consequence, the translation of in vitro or in vivo 332 
findings to human context often remains difficult. 333 
 334 
  335 
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Understanding microbiome dynamics using longitudinal studies 336 
Despite the discussed caveats, metagenome-wide association studies have identified important 337 
microbiome-disease links that can be followed up for diagnostic purposes, and revealed major 338 
co-variates of gut microbiome composition. However, most of these studies were cross-339 
sectional and hence mechanistic insights remain limited. Large-scale generation of longitudinal 340 
data, covering (i) baseline dynamics of the unperturbed gut microbiome, and (ii) the response to 341 
various perturbations (see next section), is crucial to understand the ‘wiring’ of the gut 342 
ecosystem – temporal resolution of stimulus and response can help disentangle cause-effect 343 
directionality of microbiome associations in natura (i.e., directly in the human host). 344 
Many studies have concluded that the gut microbiome is remarkably stable over time at 345 
baseline, in the absence of intervention, both in terms of taxonomic and functional composition. 346 
For example, intra-individual genus and species-level compositional variation over time is lower 347 
than inter-individual differences (see e.g., Faith et al., 2013; The Human Microbiome Project Consortium, 348 
2012, among others), an observation that has since been extended to strain-level resolution 349 
(Costea et al., 2017a; Lloyd-Price et al., 2017; Schloissnig et al., 2013). More recently, the fecal 350 
microbiome has been reported to be transcriptomically stable over time as well, albeit to a 351 
lesser extent (Abu-Ali et al., 2018). In contrast to this general temporal stability of the adult 352 
unperturbed microflora, clear successional dynamics have been described for the developing 353 
microbiome of infants (Bäckhed et al., 2015; Koenig et al., 2011; La Rosa et al., 2014), and 354 
elderly people can show a marked loss of microbiome stability depending on further lifestyle 355 
factors (Jeffery et al., 2016). 356 
All in all, however, the temporal variation of the human gut microbiota remains understudied and 357 
most of the currently published studies are statistically underpowered, either in number of 358 
individuals, in number of time points or in temporal resolution. High resolution studies with 359 
sufficient cohort sizes are essential to build predictive models of gut microbiome dynamics, 360 
which can then be challenged to model perturbation response (Bucci and Xavier, 2014; Faust et 361 
al., 2015). This will not be a trivial task: even the relatively defined community succession in 362 
neonates has proven elusive to predictive modeling, probably due to the relative importance of 363 
both maternally and environmentally contributed strains (Asnicar et al., 2017; Korpela et al., in 364 
press). 365 
 366 
Disentangling the microbiome’s ‘wiring’ using perturbations 367 
Perturbation experiments have long been a framework of choice in both systems biology 368 
(Jansen, 2003) and community ecology (Bender et al., 1984), as community-level responses to 369 
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a perturbation allow inferences about interactions between its members. Although the blind 370 
application of classical ecological theory to the microbiome is not without risk (Koskella et al., 371 
2017), the value of perturbation designs in microbial ecology has been demonstrated repeatedly 372 
(Faust et al., 2015; Shade et al., 2012). Indeed, perturbation experiments are much more 373 
informative towards the development of (dynamic) predictive models for microbial community 374 
ecology than cross-sectional studies, in particular when complemented with in vitro and in vivo 375 
approaches (see Box 2). Such a perturb-to-predict paradigm can provide testable hypotheses 376 
and will be essential towards a targeted modulation of the gut microbiome, which in turn is at the 377 
heart of translational work (see next section).  378 
Here, we review examples of how interventional studies can advance our understanding of the 379 
gut microbiome and highlight emerging trends. We use a broad definition of perturbation, 380 
including stimuli such as medication or dietary intervention. 381 
 382 
Perturbation response as a window into microbiome community structure and dynamics 383 
Whereas longitudinal analyses are essential to understand baseline microbiome dynamics, 384 
perturbation of a microbial system allows much deeper insights into its ecological makeup 385 
(Faust et al., 2015; Shade et al., 2012; Sommer et al., 2017). Arguably, the longest lasting 386 
perturbation experiment on the human gut microbiome is diet intake, as this natural process has 387 
evolved over millions of years. After adopting a more sedentary lifestyle, humans have adapted 388 
to an omnivore diet with high variety, and the impact of moderate dietary shifts should therefore 389 
be limited and transient. Indeed, several studies have shown that dietary interventions often 390 
seem to elicit only specific effects (see Zmora et al., 2016 et al. for a recent review), although 391 
more extreme shifts can show more pronounced signatures. For example, radical switches to 392 
all-plant- or animal-based diets on the microbiome have a differential impact, and specific 393 
groups of taxa respond similarly across individuals (David et al., 2014). Another study found a 394 
consistent ecosystem-wide increase in gene richness in response to an energy-restricted high-395 
protein diet in obese patients (Cotillard et al., 2013). In general, most studies to date have 396 
investigated rather broadly defined dietary shifts, e.g. to overall varying levels of non-specific 397 
nutrient classes such as proteins or carbohydrates, but the effects of defined, specific dietary 398 
interventions are only beginning to be explored. 399 
In contrast to dietary shifts, clinical interventions can be expected to elicit more drastic 400 
responses, as they can dramatically change environmental conditions in the intestine. Bowel 401 
cleansing, often performed in preparation of other treatments, may be followed by a rapid 402 
recovery of overall microbiome composition (Voigt et al., 2015), though it may trigger the 403 
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persistent loss of individual taxa (Jalanka et al., 2015). Other clinical interventions with long-404 
term microbiome effects include bariatric surgery (Tremaroli et al., 2015) or induced, iso-osmotic 405 
diarrhea. The latter has been reported to induce marked but transient effects, with post-406 
perturbation recovery following a consistent succession across subjects (Fukuyama et al., 407 
2017). Treatment with broad-spectrum antibiotics can have pronounced, persistent and often 408 
non-specific effects, and recovery of compositional state post perturbation is sometimes 409 
incomplete, due to a loss of taxa from the community (Dethlefsen and Relman, 2011; 410 
Dethlefsen et al., 2008; Jakobsson et al., 2010; Jernberg et al., 2007; Voigt et al., 2015). 411 
Similarly, treatment with the narrow-spectrum antibiotic cefprozil triggered consistent responses 412 
of individual taxa, while community-level response was stratified (Raymond et al., 2015). 413 
In general, one must note that most controlled interventional studies focus on a putative role of 414 
the microbiome in host response to perturbation, rather than on the microbiome’s response 415 
itself. Host and microbiota effects are often difficult to disentangle: while antibiotics treatment, 416 
for example, clearly affects the microbiome (which may then mediate indirect effects on the 417 
host), the independent host and microbiome responses to dietary intervention are more difficult 418 
to unravel. In consequence, many perturbation studies have been conducted in mouse models 419 
which allow to control for host effects to some extent, in spite of other limitations (Nguyen et al., 420 
2015). Moreover, in vitro approaches are gaining renewed attention (see Box 2), as these allow 421 
fairly straightforward probing of the response of communities or individual strains to specific 422 
perturbations, independently of the host (Maier and Typas, 2017). In vitro screens are scalable, can 423 
go down to the resolution of individual genes in individual strains (e.g., Galardini et al., 2017), while at 424 
the same time allowing for very broad designs, a recent example being a screen of 1,200 drugs 425 
screened against 40 gut microbial strains (Maier et al., in press). Thus, in vitro screens can 426 
serve as massive hypothesis generators to guide the study of microbiome perturbation 427 
responses in vivo, either in animal models, or directly in humans, as shown in a recent study on 428 
the impact of salt on the microbiome (Wilck et al., 2017). 429 
Nevertheless, systematic perturbation studies in humans with the sole purpose of understanding 430 
the microbial ecology of the gut microbiota will be needed as well. Larger and more controlled 431 
prospective and interventional study designs are increasingly adopted, metadata acquisition 432 
becomes more and more comprehensive and sophisticated, and data generation gets more 433 
affordable. This will enable us to probe taxonomic and functional interactions among the 434 
microbiome, and to understand the factors underlying differential perturbation response. Given 435 
the complexity of the human-microbiome symbiosis, only ‘real life’ data will yield the necessary 436 
information for building realistic predictive models. 437 
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 438 
From perturbation to prediction 439 
So far, predictive modeling of perturbation responses has proven extremely challenging (Bucci 440 
and Xavier, 2014; Faust et al., 2015), both because of complexity and variation, but also 441 
because of our limited functional understanding of the wiring of the gut microbiome (see above). 442 
Moreover, it has been argued that the microbiome’s response to many perturbations is 443 
inherently stochastic (Zaneveld et al., 2017), and therefore not fully predictable. 444 
Yet, a number of predictive models of microbiome dynamics at the level of individual taxa or 445 
taxa groups exist (Bucci and Xavier, 2014). For example, Lotka-Volterra models were used to 446 
predict community dynamics in response to Clostridium difficile infection in mice (Stein et al., 447 
2013). The resulting models could subsequently predict the success of a C. difficile-protective 448 
probiotic treatment (Buffie et al., 2014). Moreover, using complex models trained on both 449 
microbiome composition and non-microbiome features, the impact of personalized dietary 450 
interventions on select microbiome features could be predicted to some extent (Shoaie et al., 451 
2015; Zeevi et al., 2015). 452 
Despite such progress, even higher-level perturbation responses are often difficult to predict, 453 
such as the gain or loss of taxonomic and functional diversity, or the overall strength (let alone 454 
direction) of compositional shifts. This is also true for microbiome resilience – the extent to 455 
which a perturbed system recovers to a pre-perturbation state (Shade et al., 2012). As 456 
discussed above, the microbiome has been reported to be generally resilient to smaller 457 
perturbations, though more pronounced disturbances can have lasting effects. It has been 458 
argued that the differential resilience between individuals could be indicative of health and 459 
disease (Lloyd-Price et al., 2016; Sommer et al., 2017), even though the factors and 460 
mechanisms underlying microbiome resilience remain poorly understood, and though it remains 461 
challenging to predict how resilient to perturbation a given microbiome will be. 462 
  463 
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From perturbation towards modulation 464 
Empirical therapeutic modulation of the gut flora has been performed for thousands of years, for 465 
example implicitly in the use of traditional herbal medication (Xu et al., 2015) or consciously by 466 
fecal microbiota transplantation (de Groot et al., 2017). Despite a wealth of reports over the last 467 
decade, links between the gut microbiota and diseases continue to be discovered (Lynch and 468 
Pedersen, 2016), and in consequence the human gut microbiome continues to gain attention as 469 
a therapeutic target (Langdon et al., 2016; Walsh et al., 2014). 470 
Here, we review recent progress on attempts at both untargeted and targeted microbiome 471 
modulation. In the context of this review, we broadly define modulation as an intervention with 472 
the intent of pushing the gut microbiome towards a desired state. This includes, among others, 473 
fecal microbiota transplantation, probiotic and prebiotic treatment, and directed dietary 474 
interventions. 475 
 476 
Fecal microbiota transplantation (FMT) 477 
An FMT is the prime example of an untargeted microbiome modulation: stool from a (healthy) 478 
donor is transferred into the gastrointestinal tract of a recipient, with the aim of improving their 479 
health or an undesired microbiome state. FMTs have been shown to be highly efficient in the 480 
treatment of recurrent Clostridioides difficile infection (RCDI), and indeed seem more suited 481 
than antibiotics for this disease (van Nood et al., 2013). Although success is less pronounced in 482 
other areas, such as e.g. for ulcerative colitis (Narula et al., 2017) or metabolic syndrome 483 
(Vrieze et al., 2012), FMTs are explored as a treatment option for a growing list of indications, 484 
with close to 200 registered clinical trials at the time of writing (clinicaltrials.gov, accessed 485 
January 2018). An obvious long-term goal is the replacement of rather undefined donor stool 486 
samples with formulated, recipient-tailored mixes of defined microbial strains. 487 
FMTs are often preceded by preparatory antibiotics treatment or bowel cleansing in the clinical 488 
practice, and effects can be difficult to disentangle. Several studies have investigated 489 
microbiome-level effects of FMT, and reported that the treatment is followed by an increase of 490 
alpha diversity in the recipient’s microbiome, and a shift in community structure towards donor 491 
composition in RCDI patients (Fuentes et al., 2014; Seekatz et al., 2014), a trend that was also 492 
observed in inflammatory bowel disease (IBD, Vermeire et al., 2016). In contrast, post-FMT 493 
community composition was only mildly associated to recipient pre-FMT composition in trials on 494 
metabolic syndrome (Kootte et al., 2017) and ulcerative colitis (Fuentes et al., 2017), calling for 495 
higher taxonomic resolution. Indeed, at the level of strain populations, engraftment of donor 496 
strains could be demonstrated, although successful colonization was more likely if strains of the 497 
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same species were present in the recipient prior to the transplant (Li et al., 2016). Moreover, 498 
donor and recipient strains were found to co-exist in the recipient for prolonged periods of at 499 
least several months post FMT (Li et al., 2016), a finding that has since been corroborated on 500 
independent cohorts for different indications (Kumar et al., 2017; Lee et al., 2017; Moss et al., 501 
2017). 502 
While this is encouraging towards future adapted treatment options, our mechanistic 503 
understanding of the microbiome’s response to FMT remains so far insufficient. Indeed, from a 504 
microbial ecology point of view, FMTs provide a unique setup to study microbiome colonization 505 
resistance, succession and overall resilience. 506 
 507 
Probiotics 508 
Probiotics, defined as “live microorganisms which when administered in adequate amounts 509 
confer a health benefit on the host” (Hill et al., 2014), have been shown to be clinically efficient 510 
treatment options in some indications (Ford et al., 2014). In contrast to FMTs, probiotic 511 
treatment is an attempt at targeted modulation of the gut microbiota, notably by adding the 512 
probiotic to the community. However, microbiome-level effects of probiotics treatment may be 513 
mild: a recent systematic review of seven randomized clinical trials found no effects of different 514 
probiotics on microbiota composition, and no evidence for persistent probiotic engraftment 515 
(Kristensen et al., 2016). This reaffirms the notion of gut microbiota colonization resistance, both 516 
to probiotics and pathogens. Studies in mice, in contrast, have concluded that engraftment 517 
success may depend on how complementary the probiotic is to the recipient’s baseline 518 
microbiome composition. For example, administration of Clostridium scindens was found to 519 
metabolically complement the recipient’s microbiota, and to enhance colonization resistance to 520 
Clostridioides difficile (Buffie et al., 2014). This outcome was based on clinical data, mouse 521 
models and mathematical modeling, and illustrates that an ecology-inspired approach can 522 
enable successful microbiome modulation. The future of next-generation probiotics thus lies in 523 
not only supplementing beneficial functionalities, but in also providing the necessary ecological 524 
context to sustain them. Moreover, the shift of microbiome composition as a whole by 525 
supplementation of more complex mixtures of organisms will arguably soon be within reach. 526 
 527 
Prebiotics and dietary intervention 528 
Prebiotics, defined as “substrate[s] that [are] selectively utilized by host microorganisms 529 
conferring a health benefit” (Gibson et al., 2017), are another means of targeted microbiome 530 
modulation. In contrast to the direct administration of probiotics, prebiotics treatment aims to 531 
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confer a selective advantage to beneficial members of the microbiota. While several studies 532 
suggest a therapeutic potential of prebiotics for different indications (Beserra et al., 2015; Ford 533 
et al., 2014), surprisingly little is known about their effect on whole microbiome composition. 534 
Increased Prevotella/Bacteroides ratios and improved glucose metabolism have been reported 535 
to follow a transient shift to a fiber-rich diet (Kovatcheva-Datchary et al., 2015). Similarly, a fiber-536 
rich diet, supplemented by other prebiotics, shifted gut microbiome functional composition and 537 
contributed to weight loss in obese children (Zhang et al., 2015a). Treatment with inulin-type 538 
fructans was reported to trigger an increase in Bifidobacterium and Anaerostipes with hardly any 539 
community-level effects (Vandeputte et al., 2017b). 540 
Beyond the supplementation of usually defined prebiotics, diet represents a vast pool of 541 
chemical and biomolecular compounds, often implicitly amended with microbes. As such, it is an 542 
important factor in shaping microbiome composition, as discussed above (reviewed by Flint et 543 
al., 2017). In consequence, directed dietary interventions can not only provide informative 544 
perturbation experiments, but are explored as mild, microbiome-mediated therapy options (Suez 545 
and Elinav, 2017). Microbiome-wide metabolic models have been used to successfully predict 546 
microbiome metabolic responses to a dietary intervention in obese and overweight individuals, 547 
stratified by baseline microbial gene richness (Shoaie et al., 2015). Similarly, in using 548 
microbiome, clinical and dietary data to train complex models, personalized dietary interventions 549 
towards improved glycemic responses were suggested and validated in a blinded randomized 550 
trial (Zeevi et al., 2015). Although both these studies optimized for host effects, the authors were 551 
also able to predict microbiome responses to intervention, to some extent. Importantly, both 552 
studies found that the microbiome stratified intervention effects and that the response to diet 553 
might be truly individual (see Box 3). Moreover, it remains to be determined how much of these 554 
inter-individual differences in response to intervention can be attributed to microbiome-intrinsic 555 
or host factors (see Figure 2). 556 
 557 
Towards targeted and predictable modulation of the gut microbiome 558 
The potential of targeted microbiome modulation has been demonstrated in several recent 559 
studies, albeit in mouse models. For example, it was found that Clostridium sporogenes 560 
metabolizes aromatic amino acids into several compounds that accumulate in the host’s blood 561 
serum, that the replacement of wild type C. sporogenes with a genetically engineered strain in 562 
gnotobiotic mice decreased serum levels of these metabolites, and affected gut permeability 563 
and host immune response (Dodd et al., 2017). More recently, it was reported that tungstate 564 
treatment selectively inhibited overgrowth of certain Enterobacteriaceae and ameliorated 565 
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symptoms in a murine colitis model (Zhu et al., 2018). The authors had previously found that 566 
molybdenum-dependent enzymes (that are inhibited by tungsten) were implied in 567 
Enterobacteriaceae blooms during induced colitis in mice (Hughes et al., 2017), and this 568 
ecological and functional insight enabled a successful gut microbiome modulation. 569 
Such studies reaffirm the notion that targeted, hypothesis-driven modulation requires an 570 
understanding of the taxonomic and functional composition, the mutual interaction structure and 571 
the relevant ecological dynamics of the microbiome. As this functional understanding is only 572 
beginning to emerge, current models have limited power to predict the outcome of microbiome 573 
modulations, and for many clinically effective interventions it is unclear how the microbiome 574 
mediates host-level effects. There are numerous macro-ecological examples of unexpected or 575 
catastrophic effects of human intervention on incompletely understood ecosystems. For 576 
instance, the invasive toxic cane toad (Bufo marinus) in Australia, originally introduced as a 577 
biological pest control in the 1930ies, has since developed into a major burden on the local 578 
ecosystem (Phillips and Shine, 2004). In analogy, (rare) adverse effects have been reported for 579 
microbiome modulatory interventions, most prominently for FMT (Wang et al., 2016b), and 580 
microbiome-related causes of these remain poorly understood. 581 
The majority of studies to investigate microbiome-level effects of modulation did so at genus or 582 
species level. However, for several probiotics, only specific strains of a given species were 583 
found to be clinically effective (Kristensen et al., 2016), and the efficacy of a given strain 584 
probably depends on the recipient’s microbiome. Indeed, some strains of Escherichia coli are 585 
highly beneficial probiotics (Wassenaar, 2016), whereas others are potent pathogens (Kaper et 586 
al., 2004). This illustrates the importance of an appropriate taxonomic resolution to successful 587 
microbiome modulation (see Figure 3): precise intervention requires a precise understanding of 588 
the target system. 589 
 590 
Defining a healthy microbiome in a healthy individual 591 
The definition of appropriate target endpoints remains a central challenge to microbiome 592 
modulation, as a consensus on microbiome “health” so far remains elusive (see Lloyd-Price et 593 
al., 2016 for a recent review). Recently, a microbiome “Global Positioning System” was 594 
proposed, in which healthy and diseased states are distinguished based on multi’omic readouts 595 
(Gilbert et al., 2016). However, while some disease states may be associated to specific 596 
microbiome signatures, microbiome states that are unequivocally “healthy” across cohorts are 597 
yet to be established (Lloyd-Price et al., 2016). Others have suggested distinctly time-resolved 598 
definitions of microbiome health, e.g. with regard to distinct and characteristic patterns of 599 
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temporal variability to distinguish healthy and diseased states (Martí et al., 2017). Similarly, it 600 
has been proposed that microbiome health manifests itself in the response to perturbations, and 601 
that an “Anna Karenina” principle applies to the microbiome – that, in variation of Tolstoy, 602 
“healthy microbiomes are all alike; each unhealthy microbiome is unhealthy in its own way” 603 
(Zaneveld et al., 2017). Moreover, it has been repeatedly suggested that it is less the response 604 
to perturbation, but rather post-perturbation resilience that is a hallmark of health (Sommer et 605 
al., 2017). 606 
Certainly, any definition of microbiome health will depend on the frame of reference. From a 607 
clinical perspective, health is determined with a view of the human host – any microbiome state 608 
associated to a healthy host state could be considered “healthy”. But such a host-centric 609 
definition is arguably incomplete, and problematic for several reasons. As discussed above, 610 
links between host and microbiome are multivariate and complex, so that many diseases of the 611 
host do not necessarily carry clear and specific microbiome signatures, while even for well-612 
described associations, the direction of causality is usually unclear. And while disease-613 
associated microbiome imbalances are thus difficult to define, this has proven even more 614 
challenging for unequivocally health-associated microbiome states. Although microbiome and 615 
host health are clearly linked, multiple healthy microbiome states can probably exist within the 616 
healthy host space. 617 
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Conclusion & Perspective 619 
Our understanding of the human gut microbiome continues to evolve at a rapid pace. The 620 
census of the microbiome – the establishment of its ‘parts lists’ – is arguably approaching 621 
completion for the major prokaryotic lineages, although a surprising amount of novel diversity 622 
continues to be discovered at sub-species and strain level, implying that the identification of 623 
novel genes in the gut is ongoing. Although prokaryotic lineages contribute the vast majority of 624 
the gut microbiome by abundance, important players may still be missed as the eukaryal and 625 
viral microbiome remain incompletely charted. Metagenome-wide association studies have 626 
identified major drivers of microbiome composition and linked individual microbial taxa and 627 
genes to diseases, host lifestyle and physiology. However, they have also revealed that known 628 
factors can only account for a surprisingly small fraction of total microbiome variation, at least 629 
without stratification for microbiome state. Longitudinal studies have begun to establish a 630 
baseline on the gut microbiome’s temporal dynamics and found it to be remarkably stable over 631 
time. The study of perturbations has further advanced our functional understanding of the 632 
microbiome, both with regard to its intrinsic interaction structure – the ‘wiring’ of its parts – and 633 
to cause-effect relationships with external factors. Moreover, it is becoming increasingly clear 634 
that the microbiome mediates, stratifies and possibly personalizes host-level responses to 635 
intervention. 636 
The increasing functional understanding of the microbiome begins to be translated into practice, 637 
in form of targeted microbiome modulation. Most attempts at in vivo microbiome modulation are 638 
of therapeutic intent: researchers aim to improve the wellbeing of patients, by proxy of the 639 
microbiome. However, a consensus on desired microbial endpoints – on what a “healthy” 640 
microbiome actually is – has yet to emerge. 641 
Currently, understanding lags behind application: the underlying reasons why an untargeted 642 
intervention like FMT is effective in some cases but not others are mostly unclear, and effective 643 
informed, precise microbiome modulation is still in its infancy. This argues for a push towards 644 
more and larger-scale longitudinal and interventional studies, with an updated methodological 645 
toolkit, including multi’omic techniques and novel in vitro approaches, and with a focus less on 646 
the host, but on the microbiome in its own right. Such studies will further advance our 647 
understanding of the microbiome, have the power to elucidate missing links, and will enable us 648 
to better predict responses to intervention. The integrated study of perturbations will thereby 649 
allow us to truly advance research on the human gut microbiome, moving from association to 650 
modulation. 651 
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Box 1: Why can we explain so little of observed microbiome variation? 660 
It has been a sobering observation that the combined effect size of different microbiome co-661 
variates (both technical and biological) appears to be intriguingly low: in the Flemish Gut Flora 662 
Project and LifeLines-DEEP cohorts, the total non-redundant compositional variation explained 663 
was in the single digit percent range (Falony et al., 2016; Zhernakova et al., 2016), the influence 664 
of host genetics has been reported in a similar range (Bonder et al., 2016; Turpin et al., 2016; 665 
Wang et al., 2016a) or below (Rothschild et al., 2017), as have disease associations (Duvallet et 666 
al., 2017). This could be due to the fact that (i) there are further important uncharacterized co-667 
variates or the current ones are not measured accurately enough, that (ii) associations of 668 
individual taxa are more relevant than global compositional shifts, that (iii) intrinsic compositional 669 
constellations or stable states are resilient, that (iv) true effects can only be detected at higher 670 
taxonomic resolution (Costea et al., 2017a), or that (v) neutral or stochastic processes (drift) 671 
have a stronger impact than previously appreciated. Moreover, (vi) the gut microbiome’s 672 
intrinsic ecological dynamics and interactions, ecological succession and ecosystem maturation 673 
(Falony et al., cond. acc.) are possible factors that have so far remained understudied, in part 674 
due to a lack of longitudinal data. 675 
Nevertheless, the current total quantification of external factors to microbiome variation is 676 
probably in the range of 10-15%, and thus of significant enough effect size to consider in clinical 677 
studies, as even some individual factors can confound associations. This likely remains true 678 
even if one extends the definition of MWAS to “Microbiome-Wide Association Studies” by also 679 
taking into account other data types, such as metatranscriptomic or metabolomic readouts, as 680 
recently suggested (Gilbert et al., 2016). Therefore, the proper consideration of and stratification 681 
for known microbiome covariates as potential confounders will greatly improve the accuracy of 682 
MWAS studies, but can also inform the interpretation of longitudinal and interventional datasets. 683 
  684 
24
Box 2: Methodological advances to boost microbiome research 685 
Microbiomics, as a research field, evolves at a breakneck pace, and this is certainly true with 686 
regard to methodological advances (see Mallick et al., 2017 for a recent review). Here we 687 
highlight recent developments that we expect to make a strong impact in the near future, 688 
enabling us to tackle new questions, and further complementing the transition from 689 
observational to interventional study designs. 690 
 691 
Multi’omics 692 
High-throughput 16S rRNA amplicon and whole genome shotgun (WGS) metagenomic 693 
sequencing have boosted microbiome research for more than a decade, and these technologies 694 
continue to dominate the field. More recently, however, the taxonomic and functional census 695 
provided by metagenomics is increasingly complemented by readouts on activity, provided by 696 
metatranscriptomics, metaproteomics and metabolomics (reviewed by Franzosa et al., 2015; 697 
Mallick et al., 2017). Metabolomic analyses, in particular, have served as independent lines of 698 
evidence to confirm hypotheses generated in MWAS, for example confirming a link of microbial 699 
metabolism to cardiovascular disease (Wang et al., 2011), or the impact of gut microbiome 700 
metabolism on insulin sensitivity (Pedersen et al., 2016). 701 
Metatranscriptomic analyses provide a more direct readout on microbial gene expression 702 
profiles, and relating this information to baseline microbiome functional potential can reveal 703 
novel insights (see Abu-Ali et al., 2018; Schirmer et al., 2018 for recent examples). The gut 704 
metaproteome, in contrast, has not been analyzed on a large scale, although a few pilot-sized 705 
studies exist (Erickson et al., 2012; Heintz-Buschart et al., 2016; Kolmeder and de Vos, 2014). 706 
An important challenge to multi’omic microbiome research is integration: the different data types 707 
provide intermingled layers of evidence and need to be interpreted in light of each other, and 708 
integrated analysis concepts (Heintz-Buschart et al., 2016; Mallick et al., 2017) start challenging 709 
common conceptions on the microbiome, e.g. on the relative importance of functional plasticity 710 
(Heintz-Buschart and Wilmes, 2017). 711 
 712 
Quantitative Microbiome Profiling (QMP) 713 
Most microbiome studies rely on compositional data – relative abundances of taxa or genes are 714 
scaled by non-informative total library sizes, and compositionality effects may introduce false 715 
positive taxa-taxa or taxa-covariate associations (Faust and Raes, 2012; Friedman and Alm, 716 
2012; Weiss et al., 2017). The use of spiked-in standards (Satinsky et al., 2013), known cell 717 
numbers (Stämmler et al., 2016) or flow cytometry (Props et al., 2017; Vandeputte et al., 2017c) 718 
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can enable absolute microbial quantification. Indeed, total microbial load showed large inter-719 
individual variation, was linked to community composition, and was decreased in Crohn’s 720 
disease (Vandeputte et al., 2017c). Thus, QMP can increase sensitivity and specificity in MWAS 721 
studies. 722 
 723 
In vitro microbiomics & microfluidics 724 
While in vitro approaches have long been used to probe the microbiome in classical reductionist 725 
setups, they are currently experiencing a renaissance in high-throughput, explorative analyses. 726 
Several microfluidics-based “gut on a chip” systems provide increasingly better approximations 727 
of the human intestinal environment (Kim et al., 2012; Marzorati et al., 2014; Shah et al., 2016). 728 
At the same time, high-throughput cultivation now encompasses fastidious, anaerobic 729 
organisms (Rettedal et al., 2014), even in defined media (Tramontano et al., in press). 730 
 731 
Extended taxonomic breadth and resolution 732 
As bacteria account for the vast majority of gut flora biomass and are most accessible to 733 
cultivation, microbiome research has mostly focused on the bacterial domain. Eukaryal (Parfrey 734 
et al., 2011; Wlodarska et al., 2015), archaeal (Gaci et al., 2014), and viral (Hurwitz et al., 2016; 735 
Lesley A Ogilvie, 2015; Yutin et al., 2018) members of the gut flora have been studied in the 736 
past, but are receiving renewed attention (Conceição-Neto et al., 2017; Sokol et al., 2017). At 737 
the same time, reference genomic representation of the archaeal and bacterial domain have 738 
increased greatly, in part due to coordinated efforts to sequence type strains (Mukherjee et al., 739 
2017). This illustrates the dynamics of the field: just over a decade ago, early human fecal 740 
metagenomes contained mostly unclassifiable reads (Eckburg et al., 2005), and even in 2013, 741 
only around half the reads in a gut metagenome mapped to reference genomes (Sunagawa et 742 
al., 2013). Only a few years later, this gap may soon be closed, at least for the major prokaryotic 743 
lineages (e.g., Zhou et al., 2018). 744 
This increase in taxonomic coverage is complemented by a similar increase in taxonomic 745 
resolution. Following a first mapping of the landscape of microbial Single Nucleotide Variants 746 
(SNVs) in the microbiome (Schloissnig et al., 2012), several tools to call microbial SNVs and to 747 
profile subspecies to strain-level variation have been developed (Costea et al., 2017c; Nayfach 748 
et al., 2016; Quince et al., 2017; Scholz et al., 2016; Truong et al., 2017) and applied to the 749 
human gut microbiome. Several species-level observations of the Human Microbiome Project 750 
were recently extended to strain level (Lloyd-Price et al., 2017), and associations of subspecies 751 
to co-variates were reported that were not apparent at lower taxonomic resolution (Costea et al., 752 
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2017a). This indicates that a resolution subordinate to species may help uncover novel and 753 
previously overlooked microbiome features and links. 754 
  755 
27
Box 3: The microbiome stratifies and personalizes host response to perturbations 756 
It is becoming increasingly clear that inter-individual microbiome variation is associated to 757 
differential response to perturbations. The human gut microbiome stratifies into distinct 758 
compositional types, termed enterotypes (Arumugam et al., 2011; Costea et al., 2018). First 759 
studies suggest that enterotypes are stable over time (Costea et al., 2018; Ding and Schloss, 760 
2014), perhaps even upon short-term dietary intervention (Roager et al., 2014; Wu et al., 2011). 761 
Enterotypes may contribute to several microbiome-disease associations, and have been linked 762 
to differential pharmacokinetics and drug metabolism (see Costea et al., 2018 for a recent 763 
review). For example, it was shown that Prevotella copri and Bacteroides vulgatus, two hallmark 764 
species underlying enterotype splits, mediate insulin resistance (Pedersen et al., 2016). The 765 
Prevotella/Bacteroides ratio was also found to predict improved glucose metabolism upon a 766 
dietary intervention (Kovatcheva-Datchary et al., 2015), and enterotype was found to be 767 
predictive of the response to treatment with the antibiotic cefprozil (Raymond et al., 2015), 768 
reinforcing the idea that enterotypes may underlie stratified responses to perturbation. 769 
Several studies have demonstrated stratification of drug responses by specific microbiome 770 
features (recently reviewed by Vázquez-Baeza et al., 2018). For example, specific strains of 771 
Eggerthella lenta have been shown to metabolize the cardiac drug digoxin, rendering it 772 
inefficient in some patients (Haiser et al., 2013). The efficacy of anti-PD1 and anti-CTLA4 773 
chemotherapy in melanoma patients has been shown to depend on the gut microbiome, with 774 
predictive compositional differences between treatment responders and non-responders 775 
(Gopalakrishnan et al., 2018; Matson et al., 2018; Routy et al., 2017; Sivan et al., 2015; Vetizou 776 
et al., 2015). Similarly, recent work in C. elegans demonstrated how gut bacteria differentially 777 
modulate the metabolism of fluoropyrimidine chemotherapeutics (García-González et al., 2017; 778 
Scott et al., 2017). 779 
The microbiome is also thought to mediate host response to dietary intervention (Sonnenburg 780 
and Bäckhed, 2016), although in this case, even more complex and personalized patterns have 781 
emerged (Zmora et al., 2016). It was reported that complex models (including lifestyle and blood 782 
parameters beyond microbiome features) could successfully predict response to dietary 783 
intervention, as validated in a randomized control study (Zeevi et al., 2015). Similarly, 784 
microbiota-wide metabolic models could successfully predict differential effects of a dietary 785 
intervention (Shoaie et al., 2015). 786 
Such studies illustrate how the microbiome may mediate and therefore stratify and personalize 787 
host-level response to intervention, and that microbiome stratification is a relevant factor to 788 
account for in practice.  789 
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Figure 1. 790 
The route towards targeted microbiome modulation entails three consecutive and mutually 791 
dependent lines of investigation. A ‘parts list’ of the microbiome’s structure and function has now 792 
been mostly established, and metagenome-wide association studies (MWAS) have identified 793 
important co-variates of microbiome composition (see Figure 2). At the same time, longitudinal 794 
studies have started to provide important insights into the microbiome’s intrinsic dynamics. 795 
Taken together, these provide first cues towards a functional understanding of the gut 796 
microbiome. Perturbation experiments can significantly extend this, while also providing insights 797 
into the microbiome’s ecological dynamics – the ‘wiring’ of the system in terms of interactions 798 
between its parts. An integrated functional understanding will be essential towards translating 799 
microbiome research into targeted modulations, with dedicated benefits for the human host. 800 
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Figure 2. 802 
Microbiome composition is associated to several known co-variates. Microbiome-extrinsic 803 
factors can be empirically classified into three categories, host-intrinsic, host-extrinsic and 804 
environmental. Moreover, microbiome state feeds back upon itself and thereby contributes to 805 
compositional variation between individuals. Clearly, these categories overlap, and many factors 806 
are also associated to each other. For example, diet contains microbes from environmental 807 
strain pools which may colonize the gut or even, in the case of food poisoning, trigger a shift into 808 
a diseased microbiome state that subsequently becomes entrenched intrinsically, but also 809 
prompts medication. In practice, it is therefore challenging to disentangle the effect size of 810 
individual factors, and it is often necessary to stratify for other co-variates, in particular also for 811 
microbiome state (see Box 3). Indeed, the overall effect of known co-variates on human gut 812 
microbiome variation is surprisingly small (Box 1). 813 
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Figure 3. 815 
Microbiome research advances rapidly, but current approaches abstract the gut microbiome via 816 
gradual approximations from different angles. A few of these access routes are depicted and 817 
categorized here, and the required level of abstraction may vary between scientific questions or 818 
study designs. A) Microbial composition is usually determined at genus level based on 16S 819 
rRNA amplicon data, although many features in association studies emerge at higher resolution. 820 
More recently, the focus shifts further to reach the level of strains, the preferred taxonomic unit 821 
in microbiology. B) Functional associations are often determined for entire functional classes or 822 
more fine-grained functional units, although even individual genes can be informative in some 823 
contexts. C) Microbiome associations have been tested at the level of entire populations or of 824 
certain cohorts, though it is becoming increasingly clear that stratification is often necessary to 825 
increase observed signals. In some instances, associations are specific even at the level of 826 
individuals. D) For experimental access, simpler systems allow for higher throughput, but they 827 
are also less representative of the microbiome in natura, i.e. in humans with an individual 828 
environment. 829 
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